Intellia Therapeutics, Inc. to Post FY2017 Earnings of ($1.71) Per Share, Oppenheimer Holdings Forecasts (NTLA)
Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Oppenheimer Holdings dropped their FY2017 earnings per share (EPS) estimates for Intellia Therapeutics in a note issued to investors on Tuesday. Oppenheimer Holdings analyst L. Cann now forecasts that the company will post earnings of ($1.71) per share for the year, down from their prior forecast of ($1.66). Oppenheimer Holdings has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Intellia Therapeutics’ Q4 2017 earnings at ($0.46) EPS, Q1 2018 earnings at ($0.52) EPS, Q2 2018 earnings at ($0.58) EPS, Q3 2018 earnings at ($0.51) EPS, Q4 2018 earnings at ($0.55) EPS, FY2018 earnings at ($2.16) EPS, FY2019 earnings at ($3.47) EPS, FY2020 earnings at ($4.74) EPS and FY2021 earnings at ($3.72) EPS.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 27.19% and a negative net margin of 215.92%. The company had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. During the same quarter last year, the firm posted ($0.22) EPS. The firm’s revenue for the quarter was up 49.0% on a year-over-year basis.
NTLA has been the topic of a number of other reports. Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a report on Tuesday, August 29th. Jefferies Group LLC set a $42.00 price objective on Intellia Therapeutics and gave the company a “buy” rating in a research report on Tuesday. ValuEngine upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. Wedbush reiterated an “ourperform” rating and set a $25.00 price objective (down previously from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. Finally, Leerink Swann upped their price objective on Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $29.50.
Institutional investors and hedge funds have recently modified their holdings of the business. Neuberger Berman Group LLC increased its position in Intellia Therapeutics by 14.9% in the second quarter. Neuberger Berman Group LLC now owns 49,517 shares of the company’s stock worth $792,000 after buying an additional 6,431 shares in the last quarter. American Century Companies Inc. purchased a new stake in Intellia Therapeutics in the second quarter worth about $583,000. Bank of Montreal Can increased its position in Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after buying an additional 7,222 shares in the last quarter. OxFORD Asset Management LLP purchased a new stake in Intellia Therapeutics in the second quarter worth about $1,132,000. Finally, Rhumbline Advisers purchased a new stake in Intellia Therapeutics in the second quarter worth about $275,000. Institutional investors and hedge funds own 47.77% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.